Chengdu Easton Biopharmaceuticals Co Ltd
SSE:688513

Watchlist Manager
Chengdu Easton Biopharmaceuticals Co Ltd Logo
Chengdu Easton Biopharmaceuticals Co Ltd
SSE:688513
Watchlist
Price: 35.07 CNY -3.55% Market Closed
Market Cap: 6.2B CNY
Have any thoughts about
Chengdu Easton Biopharmaceuticals Co Ltd?
Write Note

Chengdu Easton Biopharmaceuticals Co Ltd
Non-Reccuring Items

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Chengdu Easton Biopharmaceuticals Co Ltd
Non-Reccuring Items Peer Comparison

Comparables:
H
3692
600436
600276
000538
S
688506

Competitive Non-Reccuring Items Analysis
Latest Figures & CAGR of Competitors

Company Non-Reccuring Items CAGR 3Y CAGR 5Y CAGR 10Y
Chengdu Easton Biopharmaceuticals Co Ltd
SSE:688513
Non-Reccuring Items
ÂĄ133.3k
CAGR 3-Years
-47%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Non-Reccuring Items
ÂĄ12.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Non-Reccuring Items
ÂĄ3.6m
CAGR 3-Years
-56%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Non-Reccuring Items
ÂĄ2.6m
CAGR 3-Years
-16%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Yunnan Baiyao Group Co Ltd
SZSE:000538
Non-Reccuring Items
ÂĄ3.7m
CAGR 3-Years
N/A
CAGR 5-Years
-21%
CAGR 10-Years
N/A
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Non-Reccuring Items
ÂĄ146.4k
CAGR 3-Years
-31%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Chengdu Easton Biopharmaceuticals Co Ltd's Non-Reccuring Items?
Non-Reccuring Items
133.3k CNY

Based on the financial report for Dec 31, 2023, Chengdu Easton Biopharmaceuticals Co Ltd's Non-Reccuring Items amounts to 133.3k CNY.

What is Chengdu Easton Biopharmaceuticals Co Ltd's Non-Reccuring Items growth rate?
Non-Reccuring Items CAGR 3Y
-47%

Over the last year, the Non-Reccuring Items growth was -50%. The average annual Non-Reccuring Items growth rates for Chengdu Easton Biopharmaceuticals Co Ltd have been -47% over the past three years .

Back to Top